S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NYSE:NVS

Novartis (NVS) Competitors

$97.86
+0.08 (+0.08%)
(As of 05/26/2023 07:00 PM ET)
Compare
Today's Range
$97.73
$98.83
50-Day Range
$81.96
$104.91
52-Week Range
$74.09
$105.56
Volume
2.95 million shs
Average Volume
2.13 million shs
Market Capitalization
$207.42 billion
P/E Ratio
30.11
Dividend Yield
2.32%
Price Target
$82.25

NVS vs. PFE, AZN, ABT, ABBV, BMY, MRK, SNY, VRTX, REGN, and ZTS

Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include Pfizer (PFE), AstraZeneca (AZN), Abbott Laboratories (ABT), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Merck & Co., Inc. (MRK), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Zoetis (ZTS). These companies are all part of the "pharmaceutical preparations" industry.

Novartis vs.

Novartis (NYSE:NVS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Pfizer had 29 more articles in the media than Novartis. MarketBeat recorded 35 mentions for Pfizer and 6 mentions for Novartis. Pfizer's average media sentiment score of 0.42 beat Novartis' score of 0.41 indicating that Pfizer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pfizer
12 Very Positive mention(s)
10 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
4 Very Negative mention(s)
Neutral

Novartis pays an annual dividend of $2.27 per share and has a dividend yield of 2.3%. Pfizer pays an annual dividend of $1.64 per share and has a dividend yield of 4.4%. Novartis pays out 69.8% of its earnings in the form of a dividend. Pfizer pays out 32.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

8.1% of Novartis shares are owned by institutional investors. Comparatively, 67.6% of Pfizer shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pfizer has higher revenue and earnings than Novartis. Pfizer is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$52.22 billion3.97$6.96 billion$3.2530.11
Pfizer$100.33 billion2.12$31.37 billion$5.087.40

Novartis has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Pfizer received 945 more outperform votes than Novartis when rated by MarketBeat users. Likewise, 69.54% of users gave Pfizer an outperform vote while only 61.51% of users gave Novartis an outperform vote.

CompanyUnderperformOutperform
NovartisOutperform Votes
521
61.51%
Underperform Votes
326
38.49%
PfizerOutperform Votes
1466
69.54%
Underperform Votes
642
30.46%

Pfizer has a net margin of 31.25% compared to Novartis' net margin of 13.78%. Pfizer's return on equity of 37.53% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis 13.78% 23.29% 11.64%
Pfizer 31.25% 37.53% 18.08%

Novartis currently has a consensus target price of $82.25, indicating a potential downside of 15.95%. Pfizer has a consensus target price of $47.33, indicating a potential upside of 25.89%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
2 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.09
Pfizer
0 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.31

Summary

Pfizer beats Novartis on 18 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVS vs. The Competition

MetricNovartisPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$207.42B$5.86B$4.51B$14.26B
Dividend Yield2.33%2.71%2.41%4.08%
P/E Ratio30.1110.28139.4120.57
Price / Sales3.97347.783,617.438.81
Price / Cash15.5319.9022.0315.16
Price / Book3.494.754.596.84
Net Income$6.96B$189.18M$117.49M$891.72M
7 Day Performance-2.38%-3.70%-2.36%-1.22%
1 Month Performance-4.59%1.59%0.96%-2.03%
1 Year Performance7.00%16.78%19.55%-10.35%

Novartis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFE
Pfizer
3.3335 of 5 stars
$39.64
+2.3%
$47.33
+19.4%
-30.3%$223.78B$100.33B7.8083,000High Trading Volume
AZN
AstraZeneca
2.5014 of 5 stars
$74.07
-0.5%
$126.00
+70.1%
+7.6%$229.59B$44.35B48.7383,500Short Interest ↓
ABT
Abbott Laboratories
3.0114 of 5 stars
$105.74
-2.3%
$122.37
+15.7%
-11.8%$183.88B$43.65B32.14115,000Short Interest ↑
ABBV
AbbVie
2.7366 of 5 stars
$142.52
-1.6%
$163.40
+14.7%
-8.3%$255.65B$56.74B33.6950,000Short Interest ↓
BMY
Bristol-Myers Squibb
2.478 of 5 stars
$66.53
+1.1%
$79.43
+19.4%
-16.2%$139.77B$46.16B19.4034,300
MRK
Merck & Co., Inc.
2.854 of 5 stars
$113.27
-1.1%
$120.75
+6.6%
+19.3%$287.42B$59.28B22.1269,000Dividend Announcement
SNY
Sanofi
2.4991 of 5 stars
$54.39
+0.8%
$94.50
+73.7%
-4.8%$137.17B$45.31B19.4991,573Dividend Cut
VRTX
Vertex Pharmaceuticals
2.0824 of 5 stars
$333.51
-1.9%
$352.59
+5.7%
+20.6%$85.90B$8.93B26.554,800
REGN
Regeneron Pharmaceuticals
2.6277 of 5 stars
$748.56
-0.4%
$850.21
+13.6%
+4.7%$81.84B$12.17B20.3411,851
ZTS
Zoetis
2.8877 of 5 stars
$172.67
-3.8%
$221.14
+28.1%
-4.3%$79.79B$8.08B38.9813,800Short Interest ↓

Related Companies and Tools

This page (NYSE:NVS) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -